SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted. Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for...
and others. Dash Bio's mission is bold but urgent: to rebuild drug development for a modern biotech era. While drug discovery has seen massive innovation through AI, mRNA, and CRISPR, drug development — the 7–12 year, multi-billion-dollar black...
BD (Becton, Dickinson and Company) a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The...
Duality Biotherapeutics' partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical...
Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide...
launch joint space missions focused on high-throughput biotechnology research. High-throughput screening (HTS) is a drug discovery process that allows for the rapid testing of thousands of chemical compounds to identify potential new medicines. The...
The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics...
(CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower...
Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...
Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single...
NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present...
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), announced the...
OneCell Diagnostics announced its launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single cell resolution,...
Bruker Corporation announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic...
JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, is announcing it will open a lab in the Discovery Oasis biotechnology space in Phoenix, Arizona. An expansive 120-acre development, Discovery Oasis is envisioned as...
CollPlant's BioInk products are ideal for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems used for drug discovery and regenerative medicine applications and are designed to be compatible with in-vitro human-based systems like...
A landmark clinical trial co-led by Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes in women with antiphospholipid syndrome...
Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. As part of this...
